|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-15.60/-3.76
|
企业价值
55.26B
|
资产负债 |
每股账面净值
33.44
|
现金流量 |
现金流量率
--
|
损益表 |
收益
6.75B
|
每股收益
23.72
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 09:04 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |